Clinical Conference 10/23/07. 76 y.o. with h/o HTN, presented to Palos ER with SSCP SH: remote tob FH: no early CAD All: NKDA Meds: lisinopril 5mg.

Slides:



Advertisements
Similar presentations
Cardiogenic Shock ……………………….and Then Some SCAI C3 Summit Chicago May 12-13, 2006 “I’m Not Dead Yet” Jeffrey F. Bleakley, University of Rochester.
Advertisements

MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.
“ If physicians would read two articles per day out of the six million medical articles published annually, in one year, they would fall 82 centuries behind.
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.
Relationship of Time to Treatment and Door-to-Balloon Time to Mortality in Patients with Acute Myocardial Infarction Treated with Primary Angioplasty Christopher.
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
Primary PCI Treatment of choice for Acute MI.
ST-Elevation Myocardial Infarction & Cardiogenic Shock - What Should We Do? Advanced Angioplasty 2008 Dan Blackman Leeds General Infirmary.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Arthur Stillman, M.D., Ph.D., PI Pamela Woodard, M.D., Study Co-chair Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Diagnostic.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction Results of the Antithrombotics.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
Cardiogenic Shock Diagnosis, Treatment and Guidelines Mladen I. Vidovich, MD April 5, 2007.
ACS and Thrombosis in the Emergency Setting
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Management Of AMI Does time matter?? What is the best strategy: PPCI Vs TT.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
Tarunjit Singh Department of Internal Medicine Westchester Medical Center New York Medical College Valhalla NY.
Primary Angioplasty and Hemodynamic Support in Cardiogenic Shock Department of Internal Medicine, College of Medicine, Yonsei University Hyuck Moon Kwon,
Revascularizaton of Ischemic DCM Percutaneous Revascularization and Hemodynamic Support Matthew R. Wolff, M.D. University of Wisconsin Disclosures: Cordis.
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
IRIS Post-hoc Analysis Background IRIS compared the safety and efficacy of early ICD implantation with medical treatment alone in 898 patients at high.
Rescue Angioplasty versus Conservative Therapy or Repeat Thrombolysis Trial Presented at American Heart Association Scientific Sessions 2004 Presented.
Update of 2013 ACCF/AHA Guidelines for STEMI Junbo Ge MD,FACC,FESC,FSCAI Zhongshan Hospital, Fudan University.
Does early beta-blockade decrease mortality in STEMI?
Journal Club Jeffrey P Schaefer, MD April 16, 2007.
Case 1 37-year old male comes to the hospital complaining of palpitation for 8 months, no other symptoms: no sweating, wt loss,ischaemic chest pain, anxiety.
Clinical Trial Results. org Characteristics, Management, and Outcomes of 5,557 Patients Age ≥90 Years With Acute Coronary Syndromes: Results From the CRUSADE.
Case 60 F with PMH HTN, DM, CVA presented to UNC ED CC: seizure. Per the daughter the pt was walking and all of a sudden fell and her whole body started.
1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.
AB 1/03 Non-Coronary Intervention Circulatory Support Advanced Angioplasty 2003 Andreas Baumbach Bristol Royal Infirmary.
Acute Coronary Syndromes Risk-Stratification Pathophysiology Diagnosis Initial Therapy Risk-Stratification Risk-Stratification Invasive vs Conservative.
Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes Results From the A to Z Trial JA de Lemos, DA Morrow, SA Wiviott,
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
Door to Balloon Time: Does it Matter? Tale of Two Studies.
Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.
Messy Inferior STEMI J. Jeffrey Marshall, MD, FSCAI December 8, 2012.
Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Elective Intra-aortic Balloon Counterpulsation During.
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
Date of download: 6/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Reduction in Treatment Times Through Formalized.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Interesting-Didactic Cases
A Clinical profile of patients enrolled in the Pakistan ACS registry
University of Chicago Medicine
Nat. Rev. Cardiol. doi: /nrcardio
T1: Post ACS Treatment Tutoring
Effect of Obesity on In-Hospital Mortality in Patients with Cardiogenic Shock Complicating AMI Obesity is paradoxically associated with favorable mortality.
European Heart Association Journal 2007 April
A Hard Look at Cardiogenic Shock: IABP-SHOCK II Revisited
TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.
Invasive versus conservative treatment in unstable coronary syndromes
The European Society of Cardiology Presented by RJ De Winter
American College of Cardiology Presented by Dr. Michel R. Le May
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
(p = 0.32 for noninferiority)
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
Atlantic Cardiovascular Patient Outcomes Research Team
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.
Presentation transcript:

Clinical Conference 10/23/07

76 y.o. with h/o HTN, presented to Palos ER with SSCP SH: remote tob FH: no early CAD All: NKDA Meds: lisinopril 5mg

OSH ER course Initial Vitals: 89/60, P96, RR 28 Defibrillation 150J x 3 Placed on 100% NRB IV lidocaine bolus and gtt Plavix 600mg, Lipitor 80mg, ASA 325mg Taken to Cath Lab

Cath Lab course Initial Central aortic pressure 92/67, then decreased to 75/52 Started on Dopamine 5mcg  20mcg Reopro IV During LAD balloon inflations, no peripheral pulse; CPR begun, Anesthesia called to intubate, IABP placed, Epinephrine/Atropine given

Cath Lab course, continued Phenylephrine gtt then Levophed gtt started  maxed Multiple balloon dilations, followed by stent placements: BMS x 3 Post-intervention, vitals BP 71/51 P112 on max Dopamine, Levophed, Phenylephrine and IABP 1:1

SHOCK Trial 302 patients with confirmed cardiogenic shock developing within 36 hours of an acute MI Randomly assigned within 12 hours of the diagnosis of shock to emergency revascularization (CABG in 40 percent and PCI in 60 percent) within six hours or to initial medical stabilization. Almost half of the patients assigned to emergency revascularization had had prior thrombolysis, and therefore underwent rescue PCI or CABG; 63 percent of patients in the medical arm also received thrombolytic therapy. Intra-aortic balloon counterpulsation was utilized in 86 percent of patients in both groups. RESULTS At 30 days, total mortality (primary end point) between the two treatment groups (47 versus 56 percent with initial medical therapy with thrombolysis, p = 0.11) At 1 year, early revascularization was associated with a lower mortality rate: 53 versus 66 percent At 6 years, mortality in revascularization group was 67 versus 80 percent with medical stabilization. The benefit of early revascularization was similar between patients both older and younger than 75 years.

SHOCK TRIAL: PCI versus CABG 128 patients with predominant left ventricular failure who underwent emergency revascularization in the SHOCK trial -37% patients underwent CABG versus, 63% PCI -CABG patients were more likely to have DM and 3V or LM disease -87% of CABG patients had complete revascularization versus 23% of PCI patients RESULTS: -Overall survival was similar at 30 days (57 with CABG versus 56 percent with PCI) and one year (47 versus 52 percent).

Compared LVAD after CABG versus LVAD alone Retrospective review of 74 patients who underwent LVAD after CABG or LVAD alone for AMI and cardiogenic shock. -28 w/ LVAD only -46 with LVAD after CABG RESULTS: -CABG + LVAD group had: -lower bridge to transplantation (45.50% vs 70.40%, P.041) -higher early mortality (39.10% vs 14.30%, P.020) -lower 6-month survival (54% vs 89%, p=0.006) -lower 12-month survivals (52% vs 82%, p=0.006)

Retrospective review of 138 consecutive cases of Cardiogenic shock and AMI Three groups of patients, all received intensive medical management and IABP: -conservative group (43 pts): A. intensive medical management and IABP alone -aggressive groups (95 pts): B. Revascularization (PCI or CABG) (77pts) C. Circulatory support/transplant (18 pts)

Improved 5 year survival in aggressive group. Greatest benefit (reduced in-hospital mortality) seen in patients who received circulatory support i.e. LVAD, LVAD as bridge to transplant